Lysophosphatidic acid receptor agonists and antagonists (WO2010051053)

Bibliography

• Tigyi G, . Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 2010;161(2):241-70
   PubMedGoogle Scholar
• van Meeteren LA, Ruurs P, Christodoulou E, Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem 2005;280(22):21155-61
   PubMedGoogle Scholar
• Ye X, Ishii I, Kingsbury MA, Lysophosphatidic acid as a novel cell survival/apoptotic factor. Biochim Biophys Acta 2002;1585(2-3):108-13
   PubMedGoogle Scholar
• Radeff-Huang J, Seasholtz TM, Matteo RG, G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 2004;92(5):949-66
   PubMedGoogle Scholar
• Deng W, Shuyu E, Tsukahara R, The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology 2007;132(5):1834-51
   PubMedGoogle Scholar
• E S, Lai YJ, Tsukahara R, Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect. J Biol Chem 2009;284(21):14558-71
   PubMedGoogle Scholar
• Chun JJM, Weiner JA, Wickens PL, Methods using a lysophosphatidic acid receptor agonist for promoting survival of myelin-producing cells. (The Regents of the University of California, USA; Allelix Biopharmaceuticals Inc.). Application: WO2000009139, 37 pp; 2000
   Google Scholar
• Kanan E, Kondo H, Shishikura J, benzyl-12b-methyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine derivatives as LPA receptor agonists. (Astellas Pharma Inc., Japan). Application: JP2008297278, 15 pp; 2008
   Google Scholar
• Gududuru V. LPA Receptor Agonists and Antagonists. RXBIO, Inc.: Application: WO2010051053, 66 pp; 2010
   Google Scholar
• Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer 2010;102(6):941-6
   Google Scholar
• Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3(8):582-91
   PubMedGoogle Scholar
• Murph M, Mills GB, . Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Mol Med 2007;9(28):1-18
   PubMedGoogle Scholar
• Pua TL, Wang FQ, Fishman DA. Roles of LPA in ovarian cancer development and progression. Future Oncol 2009;5(10):1659-73
   PubMedGoogle Scholar
• Ramachandran S, Shida D, Nagahashi M, Lysophosphatidic acid stimulates gastric cancer cell proliferation via ERK1-dependent upregulation of sphingosine kinase 1 transcription. FEBS Lett 2010;584(18):4077-82
   Google Scholar
• Jeon ES, Lee IH, Heo SC, Mesenchymal stem cells stimulate angiogenesis in a murine xenograft model of A549 human adenocarcinoma through an LPA1 receptor-dependent mechanism. Biochim Biophys Acta 2010;1801(11):1205-13
   Google Scholar
• Durgam GG, Virag T, Walker MD, Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem 2005;48(15):4919-30
   PubMedGoogle Scholar
• Virag T, Elrod DB, Liliom K, Fatty alcohol phosphates are subtype-selective agonists and antagonists of LPA receptors. Mol Pharmacol 2003;63(5):1032-42
   PubMedGoogle Scholar
• Hasegawa Y, Erickson JR, Goddard GJ, Identification of a phosphothionate analogue of lysophosphatidic acid as a selective agonist of the LPA3 receptor. J Biol Chem 2003;278(14):11962-9
   PubMedGoogle Scholar
• Xu Y, Aoki J, Shimizu K, Structure-activity relationships of fluorinated lysophosphatidic acid analogues. J Med Chem 2005;48(9):3319-27
   PubMedGoogle Scholar
• Murakami-Murofushi K, Shioda M, Kaji K, Inhibition of eukaryotic DNA polymerase alpha with a novel lysophosphatidic acid (PHYLPA) isolated from myxoamoebae of Physarum polycephalum. J Biol Chem 1992;267(30):21512-17
   PubMedGoogle Scholar
• Miller DD, Tigyi G, Durgam GG, LPA Receptor Agonists and Antagonists and Methods of Use, U.S.P.a.T. Office. The University of Tennessee Research Foundation: US7217704; 2007
   Google Scholar
• Kosanam H, Ma F, He H, Development of an LC-MS/MS assay to determine plasma pharmacokinetics of the radioprotectant octadecyl thiophosphate (OTP) in monkeys. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878(26):2379-83
   Google Scholar
• Xu Y, Qian L, Prestwich GD. Synthesis of monofluorinated analogues of lysophosphatidic acid. J Org Chem 2003;68(13):5320-30
   PubMedGoogle Scholar
• Xu Y, Qian L, Pontsler AV, Synthesis of difluoromethyl-substituted lysophosphatidic acid analogues. Tetrahedron 2004;60(1):47-53
   Google Scholar
• Xu Y, Tanaka M, Arai H, Alkyl lysophosphatidic acid and fluoromethylene phosphonate analogs as metabolically-stabilized agonists for LPA receptors. Bioorg Med Chem Lett 2004;14(21):5323-8
   PubMedGoogle Scholar
• Jiang G, Xu Y, Fujiwara Y, Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem 2007;2(5):679-90
   PubMedGoogle Scholar
• Heise CE, Santos WL, Schreihofer AM, Activity of 2-substituted LPA analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol 2001;60(6):1173-80
   PubMedGoogle Scholar
• Santos WL, Heasley BH, Jarosz R, Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid. Bioorg Med Chem Lett 2004;14(13):3473-6
   PubMedGoogle Scholar
• Murakami-Murofushi K, Kobayashi S, Onimura K, Selective inhibition of DNA polymerase-alpha family with chemically synthesized derivatives of PHYLPA, a Unique Physarum lysophosphatidic acid. Biochim Biophys Acta 1995;1258(1):57-60
   PubMedGoogle Scholar